LQDA Maintained at Buy by Jefferies, Price Target Raised to $60

Jefferies maintained its Buy rating on Liquidia Corporation (LQDA) while raising the Liquidia price target to $60 from $57 on May 11, 2026. The biotech firm trades at $53.13, reflecting strong momentum in the pulmonary hypertension space. Liquidia’s market cap sits at $4.68 billion. The analyst action signals confidence in the company’s YUTREPIA inhaled treprostinil program and commercial execution. This maintained stance comes as the stock surges 25.6% in a single day, driven by positive earnings announcements and sector tailwinds.

Jefferies Maintains Buy Rating with Raised Price Target

Jefferies kept its Buy rating intact while lifting the Liquidia price target to $60 from $57. This action reflects analyst confidence in near-term catalysts and long-term value creation. The $3 price target increase suggests 12.8% upside from current levels.

Strong Analyst Consensus Supports Rating

With 10 Buy ratings and only 1 Sell among analysts, Liquidia maintains broad support across the Street. The consensus rating of 4.0 (on a 5-point scale) indicates bullish sentiment. Two analysts rate the stock as Strong Buy, reinforcing conviction in the company’s pipeline and commercial potential.

Stock Performance Reflects Positive Momentum

LQDA jumped 25.6% in a single trading session to $53.13, with volume reaching 6.9 million shares. The 52-week range spans $11.85 to $53.74, showing dramatic recovery. This surge reflects earnings announcements and sector momentum in pulmonary hypertension treatments.

YUTREPIA Program Drives Investment Thesis

Liquidia’s lead candidate YUTREPIA represents a significant commercial opportunity in pulmonary arterial hypertension (PAH). The inhaled dry powder formulation of treprostinil offers dosing convenience versus existing therapies. Analyst upgrades increasingly focus on this program’s market potential and regulatory trajectory.

Revenue Growth and Financial Metrics

The company posted 10.3% revenue growth year-over-year, with gross margins at 98.7%. Operating cash flow grew 61.8%, signaling improving operational efficiency. Free cash flow increased 59.3%, providing runway for clinical development and commercialization investments.

Meyka AI Stock Grade Assessment

Meyka AI rates LQDA with a grade of B+, reflecting strong fundamentals relative to sector peers. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Valuation and Technical Signals

LQDA trades at a P/E ratio of 207.9, reflecting biotech growth expectations and pre-profitability status. The price-to-sales ratio of 16.1 aligns with high-growth biotech peers. Enterprise value to sales stands at 15.5x, pricing in significant future revenue expansion.

Technical Indicators Show Overbought Conditions

The RSI reading of 83.0 signals overbought territory, suggesting potential near-term consolidation. Stochastic indicators (%K at 92.3) also indicate stretched momentum. However, the Money Flow Index at 84.4 confirms strong institutional buying interest in the stock.

Cash Position Supports Development Pipeline

Liquidia maintains $2.53 per share in cash, providing financial flexibility. The current ratio of 1.49 demonstrates solid liquidity. Debt-to-equity stands at 0.53, indicating moderate leverage appropriate for a clinical-stage biotech company.

Market Outlook and Analyst Expectations

Analysts project LQDA reaching $49.34 within 12 months and $85.59 within three years. These forecasts embed assumptions about YUTREPIA commercialization success and market adoption. The three-year target implies 61% upside from current prices, supporting the bullish consensus.

Sector Tailwinds in Pulmonary Hypertension

The PAH market continues expanding with new treatment options and patient awareness. Liquidia’s inhaled formulation addresses unmet needs in dosing convenience. Competitive dynamics remain favorable given the large addressable market and limited direct competitors.

Risk Factors to Monitor

Regulatory approval timelines, competitive launches, and reimbursement decisions represent key risks. The company’s negative EPS of -$0.80 reflects ongoing R&D investments. Execution on commercial partnerships and market penetration will determine whether the $60 price target proves achievable.

Final Thoughts

Jefferies’ maintained Buy rating and raised Liquidia price target to $60 underscore confidence in the company’s strategic positioning within pulmonary hypertension treatment. The $3 increase reflects improving visibility on YUTREPIA commercialization and revenue growth trajectory. With 10 Buy ratings and strong cash generation, LQDA has momentum heading into key clinical and commercial milestones. The 25.6% single-day surge demonstrates investor enthusiasm, though overbought technical signals warrant caution on near-term pullbacks. Long-term investors should monitor YUTREPIA adoption rates, competitive dynamics, and quarterly cash burn. The $60 price target represents reasonable upside for risk-tolerant biotech investors aligned with the company’s development timeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.